David Kaminetzsky

David Kaminetzsky

Auto-generated profile, based on publicly available information

David Kaminetzsky

Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
ACAjai Chari
Ajai Chari
DVDan T. Vogl
Dan T. Vogl
MGMaria Gavriatopoulou
Maria Gavriatopoulou
ANAjay K. Nooka
Ajay K. Nooka
AYAndrew J. Yee
Andrew J. Yee
SJSundar Jagannath
Sundar Jagannath
Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma that is refractory to current therapeutic options.
1

20 March 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DVDan T. Vogl
Dan T. Vogl
DDDavid Dingli
David Dingli
RCRobert Frank Cornell
Robert Frank Cornell
CHCarol Ann Huff
Carol Ann Huff
SJSundar Jagannath
Sundar Jagannath
ASA. Keith Stewart
A. Keith Stewart
Purpose: Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods: This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results: Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion: The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.

1 August 2020 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
MKMark Kaminetzky
Mark Kaminetzky
WMWilliam Moore
William Moore
KFKush Fansiwala
Kush Fansiwala
JBJames S. Babb
James S. Babb
DKDavid Kaminetzky
David Kaminetzky
JKJane P. Ko
Jane P. Ko
Background Understanding pulmonary embolism (PE) rate and contributing comorbid, clinical, laboratory, and imaging characteristics may aid in management of pro-thombotic events in COVID-19 (COVID+)...

1 March 2022 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
FMFrancesco Maura
Francesco Maura
EBEileen M. Boyle
Eileen M. Boyle
EREven H. Rustad
Even H. Rustad
CACody Ashby
Cody Ashby
DKDavid Kaminetzky
David Kaminetzky
GMGareth John Morgan
Gareth John Morgan

1 April 2010 in Expert Review of Hematology
Verified
Journal Article
Closed access
JZJasmine Zain
Jasmine Zain
DKDavid Kaminetzky
David Kaminetzky
OOOwen A O’connor
Owen A O’connor
Cutaneous T-cell lymphomas (CTCLs) are rare lymphomas that arise primarily in the skin and are treated with skin-directed therapies in early-stage disease. Systemic therapy is indicated once skin-directed therapy is ineffective or for advanced-stage disease. CTCLs tend to be poorly responsive to chemotherapy and are incurable except for allogeneic stem cell transplantation. Recently, a new class of agents called histone deacetyalse inhibitors (HDACis) have shown remarkable activity in T-cell lymphomas in general and CTCLs in particular. Oral vorinostat and intravenous romidepsin are two HDACis that are now approved by the US FDA for use in patients with relapsed CTCLs. Several other HDACis are currently in clinical trials for CTCLs and other diseases and, although these agents vary by chemical structure and potency, the results of the ongoing clinical trials will eventually reveal if there are differences in clinical activity as well. The exact mechanism of action of these agents is unknown, but they are thought to affect the acetylation status of histones and other proteins in the cell and epigentically modulate transcription and other cellular activities. This leads to a myriad of downstream effects on cell cycle, apoptosis and differentiation. The following review summarizes the known biological mechanisms and clinical activity of various HDACis in the treatment of CTCLs and tries to define their role in the treatment paradigm of these unusual disorders.

14 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EBEileen M. Boyle
Eileen M. Boyle
PBPatrick Blaney
Patrick Blaney
JSJames H. Stoeckle
James H. Stoeckle
YWYubao Wang
Yubao Wang
HGHussein Ghamlouch
Hussein Ghamlouch
GMGareth John Morgan
Gareth John Morgan
Purpose: Chromosome 1 (chr1) copy-number abnormalities (CNA) and structural variants (SV) are frequent in newly diagnosed multiple myeloma (NDMM) and are associated with a heterogeneous impact on outcomes, the drivers of which are largely unknown. Experimental Design: A multiomic approach comprising CRISPR, gene mapping of CNAs and SVs, methylation, expression, and mutational analysis was used to document the extent of chr1 molecular variants and their impact on pathway utilization. Results: We identified two distinct groups of gain(1q): focal gains associated with limited gene-expression changes and a neutral prognosis, and whole-arm gains, which are associated with substantial gene-expression changes, complex genetics, and an adverse prognosis. CRISPR identified a number of dependencies on chr1 but only limited variants associated with acquired CNAs. We identified seven regions of deletion, nine of gain, three of chromothripsis (CT), and two of templated insertion (TI), which contain a number of potential drivers. An additional mechanism involving hypomethylation of genes at 1q may contribute to the aberrant gene expression of a number of genes. Expression changes associated with whole-arm gains were substantial and gene set enrichment analysis identified metabolic processes, apoptotic resistance, signaling via the MAPK pathway, and upregulation of transcription factors as being key drivers of the adverse prognosis associated with these variants. Conclusions: Multiple layers of genetic complexity impact the phenotype associated with CNAs on chr1 to generate its associated clinical phenotype. Whole-arm gains of 1q are the critically important prognostic group that deregulate multiple pathways, which may offer therapeutic vulnerabilities.